Medicare GLP-1 Coverage Adds 700,000 Senior Users, Lilly Claims 70% Share

Eli Lilly's chief executive disclosed that approximately 700,000 Medicare-eligible seniors have initiated GLP-1 therapy since the federal program began covering the weight-loss and diabetes drug class in July, according to remarks reported by Business News. The figures offer the clearest picture yet of how quickly expanded government coverage is translating into real-world patient uptake among older Americans.

Of those new senior users, roughly 70 percent are taking a Lilly-branded GLP-1 medication, the CEO said, signaling a dominant early market position for the Indianapolis-based drugmaker as competition in the category intensifies. Lilly's flagship GLP-1 products — used to treat obesity and Type 2 diabetes — have been among the most closely watched pharmaceuticals in the industry.

Read more California Weighs Billionaire Tax as Wealthy Eye Safe-Haven Assets →

The Medicare coverage expansion, which took effect in July, marked a significant policy shift that analysts had expected to dramatically widen the patient population eligible for GLP-1 drugs at reduced out-of-pocket cost. The 700,000 figure represents an early measure of that demand surge, though it remains unclear how the enrollment rate compares to pre-launch projections or how it may evolve as awareness grows.

The metrics underscore both the commercial opportunity and the policy stakes surrounding GLP-1 medicines. Broad Medicare uptake could accelerate federal drug spending, a concern that policymakers have flagged even as advocates argue the treatments reduce long-term costs tied to obesity-related illness. Lilly's commanding share of new senior enrollees positions the company favorably but also invites scrutiny over pricing and access equity.

Continue reading at Business News.